Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.
paper
Cited
Public
Unavailable
- Authors
- Falk, Daniel; Wang, Xin Qun; Liu, Lei; Fertig, Joanne; Mattson, Margaret; Ryan, Megan; Johnson, Bankole; Stout, Robert; Litten, Raye Z
- Year
- 2010
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 20659066
- DOI
- 10.1111/j.1530-0277.2010.01290.x
BACKGROUND: Percent subjects with no heavy drinking days (PSNHDDs), an efficacy end point recommended by the Food and Drug Administration, considers abstinent individuals or those engaging in low-risk drinking behavior as successful responders to treatment. As PSNHDD has been used infrequently in previous alcohol clinical trials, we evaluated the utility and validity of the PSNHDD outcome measure in 2 large alcohol clinical trials. METHODS: Data sets from 2 alcohol trials, COMBINE and a multisite topiramate trial, were used to analyze PSNHDDs and other traditional end points for the topiramate, naltrexone, acamprosate, and placebo groups. Effect sizes of PSNHDDs were determined for each month of active treatment and by varying grace periods-early periods in the trial where outcome is not considered in the analysis-and were compared with that of other traditional outcome measures. Long-term outcomes were compared for groups that had no heavy drinking days versus those that had heavy drinking days during active treatment. RESULTS: PSNHDD effect sizes were significant for both topiramate (0.34 and 0.25 at months 2 and 3, respectively) and naltrexone (0.24 and 0.26 at months 3 and 4, respectively). Given a 2-month grace period for naltrexone, the effect size of PSNHDDs was comparable to the effect sizes using traditional outcome measures. With a 1-month grace period for topiramate, it was greater than the majority of traditional outcome measures. Little is gained by allowing up to 1, 2, or 3 heavy drinking days as an end point. Subjects with no HDDs during treatment fared better than those with some HDDs on drinking outcomes and alcohol-related consequences during a 1-year follow-up. CONCLUSIONS: PSNHDD appears to be a clinically informative end point measure, especially when used with a grace period, and is as sensitive as most traditional outcome measures in detecting differences between the medication and placebo groups. Nonetheless, these findings should be replicated in other clinical data sets, particularly with medications that work via different mechanisms.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Glucagon-Like Peptide-1 Receptor Agonists and Alcohol Use: A Real-Word Observational Study in a Large, Integrated Health Care System. | Palzes VA et al. | β | 2026 | β |
| The Impact of Skill Utilization on Alcohol Use Outcomes Following Completion of a Brief Web-Based Alcohol Intervention. | Patton EE et al. | β | 2026 | β |
| A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. | Quddos F et al. | β | 2025 | β |
| Beyond frequency of use: Exploring additional metrics for quantifying cocaine use and their relation to life functioning and treatment outcome. | Ellis S et al. | β | 2025 | β |
| Efficacy and safety of a digital therapeutic for alcohol dependence: A multicenter, open-label, randomized controlled trial. | So R et al. | β | 2025 | β |
| N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study). | Morley K et al. | β | 2025 | β |
| Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone. | Logge WB et al. | β | 2025 | β |
| Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study. | Bouthillier A et al. | β | 2025 | β |
| Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity: a pilot study | Quddos F et al. | β | 2025 | β |
| Within-person affect dynamics among individuals in residential treatment for opioid use disorder: An ecological momentary assessment study. | Knapp KS et al. | β | 2025 | β |
| A short version of the Alcohol Consumption Consequences Evaluation Scale (ACCE10). | Sancerni-Beitia MD et al. | β | 2024 | β |
| Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics. | McClure EA et al. | β | 2024 | β |
| EndpointsΒ for Pharmacotherapy Trials for AlcoholΒ Use Disorder. | Belnap MA et al. | β | 2024 | β |
| Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder. | Haque LY et al. | β | 2024 | β |
| Medication development for AUD: A systematic review of clinical trial methodology. | Donato S et al. | β | 2024 | β |
| Reductions in Substance Use as Outcome Targets for Treatment Development. | Compton WM et al. | β | 2024 | β |
| Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder. | McCann DJ et al. | β | 2024 | β |
| The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. | Yoon G et al. | β | 2024 | β |
| Alcohol Approach Bias Is Associated With Both Behavioral and Neural Pavlovian-to-Instrumental Transfer Effects in Alcohol-Dependent Patients. | Chen K et al. | β | 2023 | β |
| Alcohol use disorder in community management of chronic liver diseases. | Leggio L et al. | β | 2023 | β |
| Bidirectional prospective associations between behavioral economic indicators and drinking patterns during alcohol use disorder natural recovery attempts. | Cheong J et al. | β | 2023 | β |
| Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence. | Brandt L et al. | β | 2023 | β |
| Life course differences in heavy episodic drinking behaviors across age, gender, and sexual identity in the United States. | Janulis P | β | 2023 | β |
| Outcomes following liver transplant for alcohol-associated liver disease: comparing alcohol-associated hepatitis and cirrhosis. | Schroeder M et al. | β | 2023 | β |
| Response to Letter to the Editors regarding 'A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis'. | Grodin EN et al. | β | 2023 | β |
| Using ecological momentary assessments of negative affect and craving during residential opioid use disorder treatment to predict patients' relapse to substance use. | Cleveland HH et al. | β | 2023 | β |
| Alcohol craving and withdrawal at treatment entry prospectively predict alcohol use outcomes during outpatient treatment. | Martins JS et al. | β | 2022 | β |
| A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis. | Grodin EN et al. | β | 2022 | β |
| Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. | Haque LY et al. | β | 2022 | β |
| Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints. | Borodovsky JT et al. | β | 2022 | β |
| Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels. | Nieto SJ et al. | β | 2022 | β |
| Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. | Louvet A et al. | β | 2022 | β |
| Efficacy and comparative effectiveness of telephone and smartphone remote continuing care interventions for alcohol use disorder: a randomized controlled trial. | McKay JR et al. | β | 2022 | β |
| Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. | Sherman BJ et al. | β | 2022 | β |
| The Impact of Exercise and Virtual Reality Executive Function Training on Cognition Among Heavy Drinking Veterans With Traumatic Brain Injury: A Pilot Feasibility Study. | Pennington DL et al. | β | 2022 | β |
| The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup. | Aldridge AP et al. | β | 2022 | β |
| Alcohol-related changes in behaviors and characteristics from the baseline to the randomization session for treatment and non-treatment seeking participants with alcohol use disorder. | Goodyear K et al. | β | 2021 | β |
| Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. | Logge WB et al. | β | 2021 | β |
| Daily meaningfulness among patients with opioid use disorder: Examining the role of social experiences during residential treatment and links with post-treatment relapse. | Knapp KS et al. | β | 2021 | β |
| Effectiveness and Utility of Mobile Device Assessment of Subjective Craving during Residential Opioid Dependence Treatment. | Cleveland HH et al. | β | 2021 | β |
| Effectiveness of spironolactone dispensation in reducing weekly alcohol use: a retrospective high-dimensional propensity score-matched cohort study. | Palzes VA et al. | β | 2021 | β |
| Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. | Garbutt JC et al. | β | 2021 | β |
| Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer? | Brandt L et al. | β | 2021 | β |
| Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment. | Mukherjee D et al. | β | 2021 | β |
| Shifts in behavioral allocation patterns as a natural recovery mechanism: Postresolution expenditure patterns. | Tucker JA et al. | β | 2021 | β |
| Within-AUD outpatient treatment heavy drinking transitions and associations with long-term outcomes. | Maisto SA et al. | β | 2021 | β |
| A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: Effects on alcohol use, cognition, and post-concussive symptoms. | Pennington DL et al. | β | 2020 | β |
| Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking alcohol use disorder individuals. | Logge WB et al. | β | 2020 | β |
| Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial. | Anton RF et al. | β | 2020 | β |
| Examining the Relationship Between Self-Reported Drinking and In-Laboratory Drinking and Craving: Is There Concordance? | DeMartini KS et al. | β | 2020 | β |
| Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. | Litten RZ et al. | β | 2020 | β |
| Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial. | Burnette EM et al. | β | 2020 | β |
| Liver transplantation in patients with alcohol-related liver disease: current status and future directions. | Mathurin P et al. | β | 2020 | β |
| Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies. | Leggio L et al. | β | 2020 | β |
| Preresolution Drinking Problem Severity Profiles Associated with Stable Moderation Outcomes of Natural Recovery Attempts. | Tucker JA et al. | β | 2020 | β |
| Psychometric Properties of the "Alcohol Consumption Consequences Evaluation" (ACCE) Scale for Young Spanish University Students. | Sancerni-Beitia MD et al. | β | 2020 | β |
| Remission From Unhealthy Drinking Among Patients With an Alcohol Use Disorder: A Longitudinal Study Using Systematic, Primary Care-Based Alcohol Screening Data. | Palzes VA et al. | β | 2020 | β |
| The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. | Loflin MJE et al. | β | 2020 | β |
| Toward Addiction Prediction: An Overview of Cross-Validated Predictive Modeling Findings and Considerations for Future Neuroimaging Research. | Yip SW et al. | β | 2020 | β |
| Consumption outcomes in clinical trials of alcohol use disorder treatment: Consideration of standard drink misestimation. | Kirouac M et al. | β | 2019 | β |
| Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. | Falk DE et al. | β | 2019 | β |
| Flexibly modeling alcohol use disorder risk: How many drinks should we count? | Linden-Carmichael AN et al. | β | 2019 | β |
| Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. | Falk DE et al. | β | 2019 | β |
| Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. | McGinnis KA et al. | β | 2019 | β |
| Patterns of Cocaine Use During Treatment: Associations With Baseline Characteristics and Follow-Up Functioning. | Roos CR et al. | β | 2019 | β |
| Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder. | Collins SE et al. | β | 2019 | β |
| Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. | Lee DC et al. | β | 2019 | β |
| What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? | Kiluk BD et al. | β | 2019 | β |
| A 22-Year Follow-Up (Range 16 to 23) of Original Subjects with Baseline Alcohol Use Disorders from the Collaborative Study on Genetics of Alcoholism. | Schuckit MA et al. | β | 2018 | β |
| Bayesian joint modelling of longitudinal data on abstinence, frequency and intensity of drinking in alcoholism trials. | Buta E et al. | β | 2018 | β |
| Change in DSM-5 Alcohol Use Disorder Criteria Count and Severity Level as a Treatment Outcome Indicator: Results from a Randomized Trial. | Kiluk BD et al. | β | 2018 | β |
| Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review. | Kranzler HR et al. | β | 2018 | β |
| Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. | O'Malley SS et al. | β | 2018 | β |
| Large variation in measures used to assess outcomes of opioid dependence treatment: A systematic review of longitudinal observational studies. | Wiessing L et al. | β | 2018 | β |
| Linear-rank testing of a non-binary, responder-analysis, efficacy score to evaluate pharmacotherapies for substance use disorders. | Holmes TH et al. | β | 2018 | β |
| Medication development in opioid addiction: Meaningful clinical end points. | Volkow ND et al. | β | 2018 | β |
| Neuroscience of Addiction: Relevance to Prevention and Treatment. | Volkow ND et al. | β | 2018 | β |
| Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. | Mooney LJ et al. | β | 2018 | β |
| Revisiting the Drinker Inventory of Consequences: An extensive evaluation of psychometric properties in two alcohol clinical trials. | Kirouac M et al. | β | 2018 | β |
| Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). | Morley KC et al. | β | 2018 | β |
| Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks? | Haass-Koffler CL et al. | β | 2017 | β |
| Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. | Dunn KE et al. | β | 2017 | β |
| Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. | Haass-Koffler CL et al. | β | 2017 | β |
| How Much Is Too Much? Patterns of Drinking During Alcohol Treatment and Associations With Post-Treatment Outcomes Across Three Alcohol Clinical Trials. | Witkiewitz K et al. | β | 2017 | β |
| Initial validation of a proxy indicator of functioning as a potential tool for establishing a clinically meaningful cocaine use outcome. | Kiluk BD et al. | β | 2017 | β |
| Late-Life Drinking Problems: The Predictive Roles of Drinking Level vs. Drinking Pattern. | Holahan CJ et al. | β | 2017 | β |
| Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article. | Litten RZ et al. | β | 2017 | β |
| Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. | Yardley MM et al. | β | 2017 | β |
| Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9-Year Follow-Up. | Kline-Simon AH et al. | β | 2017 | β |
| Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. | Schacht JP et al. | β | 2017 | β |
| Social to Moderate Alcohol Consumption Provides a Protective Effect for Functional Outcomes After Fixation of Orthopaedic Fractures. | Saleh H et al. | β | 2017 | β |
| Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study. | Witkiewitz K et al. | β | 2017 | β |
| The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. | Hauser P et al. | β | 2017 | β |
| The search for an elusive cutoff remains: Problems of binary classification of heavy drinking as an endpoint for alcohol clinical trials. | Pearson MR et al. | β | 2017 | β |
| The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients. | Edelman EJ et al. | β | 2017 | β |
| Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder. | Johnson BA | β | 2017 | β |
| Trajectories of remission and mortality over 13 years after intake to substance use treatment. | Kline-Simon AH et al. | β | 2017 | β |
| Viability of the World Health Organization quality of life measure to assess changes in quality of life following treatment for alcohol use disorder. | Kirouac M et al. | β | 2017 | β |
| Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials. | Witkiewitz K et al. | β | 2017 | β |
| A modified classification tree method for personalized medicine decisions. | Tsai WM et al. | β | 2016 | β |
| Attenuation of cocaine self-administration by chronic oral phendimetrazine in rhesus monkeys. | Czoty PW et al. | β | 2016 | β |
| Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. | Litten RZ et al. | β | 2016 | β |
| Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. | Czoty PW et al. | β | 2016 | β |
| Is the Construct of Relapse Heuristic, and Does It Advance Alcohol Use Disorder Clinical Practice? | Maisto SA et al. | β | 2016 | β |
| Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. | Kiluk BD et al. | β | 2016 | β |
| Missing Data in Alcohol Clinical Trials with Binary Outcomes. | Hallgren KA et al. | β | 2016 | β |
| Questioning the validity of the 4+/5+ binge or heavy drinking criterion in college and clinical populations. | Pearson MR et al. | β | 2016 | β |
| Randomized Trial of Computerized Cognitive Behavioral Therapy for Alcohol Use Disorders: Efficacy as a Virtual Stand-Alone and Treatment Add-On Compared with Standard Outpatient Treatment. | Kiluk BD et al. | β | 2016 | β |
| Reductions in Healthcare Costs Following Alcohol Treatment: Moving Toward Low-Risk Drinking End Points in Alcohol Clinical Trials. | Witkiewitz K et al. | β | 2016 | β |
| Relations Between Cognitive Functioning and Alcohol Use, Craving, and Post-Traumatic Stress: An Examination Among Trauma-Exposed Military Veterans With Alcohol Use Disorder. | Heinz AJ et al. | β | 2016 | β |
| Role of the Ξ±1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. | Kenna GA et al. | β | 2016 | β |
| The Relationship Between End-of-Treatment Alcohol Use and Subsequent Healthcare Costs: Do Heavy Drinking Days Predict Higher Healthcare Costs? | Aldridge AP et al. | β | 2016 | β |
| An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. | Gueorguieva R et al. | β | 2015 | β |
| Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. | Hammond CJ et al. | β | 2015 | β |
| Guidelines for the Reporting of Treatment Trials for Alcohol Use Disorders. | Witkiewitz K et al. | β | 2015 | β |
| Pain as a predictor of heavy drinking and any drinking lapses in the COMBINE study and the UK Alcohol Treatment Trial. | Witkiewitz K et al. | β | 2015 | β |
| Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. | Gueorguieva R et al. | β | 2015 | β |
| Predictors of posttreatment drinking outcomes in patients with alcohol dependence. | FlΓ³rez G et al. | β | 2015 | β |
| Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders. | Witkiewitz K et al. | β | 2015 | β |
| Subgroup Identification in Personalized Treatment of Alcohol Dependence. | Hou J et al. | β | 2015 | β |
| Alcohol use disorder clinical course research: informing clinicians' treatment planning now and in the future. | Maisto SA et al. | β | 2014 | β |
| Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials. | Falk DE et al. | β | 2014 | β |
| Gabapentin treatment for alcohol dependence: a randomized clinical trial. | Mason BJ et al. | β | 2014 | β |
| Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials. | Witkiewitz K et al. | β | 2014 | β |
| Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT. | Gueorguieva R et al. | β | 2014 | β |
| Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs. | Litten RZ et al. | β | 2014 | β |
| Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. | Kranzler HR et al. | β | 2014 | β |
| Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial. | Batki SL et al. | β | 2014 | β |
| Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. | Carroll KM et al. | β | 2014 | β |
| What happens in treatment doesn't stay in treatment: cocaine abstinence during treatment is associated with fewer problems at follow-up. | Kiluk BD et al. | β | 2014 | β |
| Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. | Johnson BA et al. | β | 2013 | β |
| Missing data in alcohol clinical trials: a comparison of methods. | Hallgren KA et al. | β | 2013 | β |
| Modeling longitudinal drinking data in clinical trials: an application to the COMBINE study. | DeSantis SM et al. | β | 2013 | β |
| PDYN rs2281285 variant association with drinking to avoid emotional or somatic discomfort. | Preuss UW et al. | β | 2013 | β |
| Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders. | Kline-Simon AH et al. | β | 2013 | β |
| Pretreatment alcohol drinking goals are associated with treatment outcomes. | Dunn KE et al. | β | 2013 | β |
| "Success" following alcohol treatment: moving beyond abstinence. | Witkiewitz K | β | 2013 | β |
| Temptation to drink as a predictor of drinking outcomes following psychosocial treatment for alcohol dependence. | Witkiewitz K | β | 2013 | β |
| Variation in Mu-Opioid Receptor Gene <i>(OPRM1)</i> as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. | Chen AC et al. | β | 2013 | β |
| A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. | Fertig JB et al. | β | 2012 | β |
| A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men. | Morgenstern J et al. | β | 2012 | β |
| Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. | Gueorguieva R et al. | β | 2012 | β |
| Factors predicting change in frequency of heavy drinking days among alcohol-dependent participants in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). | Sarsour K et al. | β | 2012 | β |
| Measures of substance consumption among substance users, DSM-IV abusers, and those with DSM-IV dependence disorders in a nationally representative sample. | Moss HB et al. | β | 2012 | β |
| Medications development to treat alcohol dependence: a vision for the next decade. | Litten RZ et al. | β | 2012 | β |
| Obtaining the optimal dose in alcohol dependence studies. | Wages NA et al. | β | 2012 | β |
| Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. | Donovan DM et al. | β | 2012 | β |
| Reanalysis of methamphetamine dependence treatment trial. | Winchell C et al. | β | 2012 | β |
| Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients. | de Beaurepaire R | β | 2012 | β |
| Text-message-based drinking assessments and brief interventions for young adults discharged from the emergency department. | Suffoletto B et al. | β | 2012 | β |
| Trajectory analyses in alcohol treatment research. | Chen J et al. | β | 2012 | β |
| Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. | Korte JE et al. | β | 2011 | β |
| Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study. | Gueorguieva R et al. | β | 2011 | β |
| Commentary on Falk. | Meyer RE | β | 2011 | β |
| Extended telephone-based continuing care for alcohol dependence: 24-month outcomes and subgroup analyses. | McKay JR et al. | β | 2011 | β |
| Opioid modulators for alcohol dependence. | Hillemacher T et al. | β | 2011 | β |
| Primary outcomes in two randomized controlled trials of treatments for cannabis use disorders. | Peters EN et al. | β | 2011 | β |
| Translational research in addiction: toward a framework for the development of novel therapeutics. | Paterson NE | β | 2011 | β |